Newsroom

Lowering blood pressure goals for adults at high risk of cardiovascular disease could save tens of thousands of lives annually and reduce costs, according to a computer simulation by researchers at Columbia University Medical Center (CUMC) and NewYork-Presbyterian. Results of the study, published today in the online edition of Hypertension and presented today at the American Society of Hypertension Annual Scientific Meeting, could prompt a revision of national hypertension treatment guidelines, which had relaxed blood pressure goals for specific high-risk patients in recent years.

The results complement recent evidence from the Systolic Blood Pressure Intervention Trial (SPRINT), which found that having a more intensive systolic blood pressure (SBP) goal of 120 mmHg in patients at high risk for cardiovascular disease reduced both cardiovascular events and mortality by about one quarter, compared with the current goal of 140 mmHg.

In 2014, the 8^th Joint National Committee (JNC8) on Detection, Evaluation, and Treatment of High Blood Pressure—appointed by the National Heart, Lung, and Blood Institute—issued new guidelines recommending that physicians aim for an SBP of 140 mmHg in adults with diabetes and/or chronic kidney disease and 150 mmHg in healthy adults over age 60. The new guidelines represented a major departure from previous JNC7 guidelines recommending SBPs of 130 mmHg and 140, mmHg for these groups, respectively, and were not endorsed by either the American Heart Association or the American College of Cardiology. Under the 2014 guidelines, over 5 million fewer individuals annually would receive drug treatment to lower their blood pressure, compared with the prior 2003 guidelines.

The CUMC team conducted a computer simulation to determine the value of adding the lower, life-saving SBP goal identified in SPRINT to the JNC7 and JNC8 guidelines for high-risk patients between the ages of 35 and 74 years. (High risk was defined as existing cardiovascular disease, chronic kidney disease, or a 10-year cardiovascular disease risk greater than 15 percent in patients older than 50 years and with a pre-treatment SBP greater than 130 mmHg.) The researchers performed the simulation on data from a national population of adults and added data on the quality-of-life impact of side effects as well as drug and blood pressure monitoring costs.

The study found that lowering treatment goals for this population in the JNC8 guidelines would prevent up to 43,000 additional deaths from cardiovascular disease each year. Adding more intensive goals to the JNC7 guidelines would prevent an additional 35,000 deaths.

The study also revealed that adding the lower SBP goals to the JNC7 and JNC8 guidelines would decrease overall treatment costs for men and would be cost-effective (representing a good value) compared with standard treatment in women.

“Hypertension treatment is cheap and effective, and fear of side effects should not dissuade physicians from treating to lower goals in high-risk individuals under 75 years of age,” said Nathalie Moise, MD, MS, lead author, assistant professor of medicine at CUMC and faculty member of the Center for Behavioral Cardiovascular Health.

Any future savings would be sensitive to higher drug costs, added Dr. Moise. “Containing drug costs will be integral to affordable implementation of intensive blood pressure goals in this high-risk group.”

“Our simulation shows that we have everything to gain by taking a more aggressive approach to lowering systolic blood pressure in patients with certain cardiovascular disease risk factors,” concluded Dr. Andrew Moran, MD, MPH, the Herbert Irving Assistant Professor of Medicine at CUMC and physician at NewYork-Presbyterian/Columbia.

The study is titled, “Comparative cost-effectiveness of conservative or intensive blood pressure treatment guidelines in adults aged 35-74 years: The CVD Policy Model.” The other contributors are: Chen Huang (Chinese Academy of Medical Sciences, Beijing, China), Anthony Rodgers (George Institute for Global Health, Sydney, New South Wales, Australia), Ciarin N. Kohli-Lynch (CUMC and University of Glasgow, Glasgow, United Kingdom), Keane Y. Tzong (CUMC), Pamela G. Coxson (University of California at San Francisco, San Francisco, CA), Kirsten Bibbins-Domingo (University of California at San Francisco), and Lee Goldman (CUMC).

The study was funded by grants from the Health Resources and Services Administration (T32HP10260), National Heart, Lung, and Blood Institute (R01 HL10747501), and the American Heart Association Founder’s Affiliate (10CRP4140089).

The authors declare no conflicts of interest.

NewYork-Presbyterian

NewYork-Presbyterian is one of the nation’s most comprehensive healthcare delivery networks, focused on providing innovative and compassionate care to patients in the New York metropolitan area and throughout the globe. In collaboration with two renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, ground-breaking research and clinical innovation.

NewYork-Presbyterian has four major divisions: NewYork-Presbyterian Hospital is ranked #1 in the New York metropolitan area by U.S. News and World Report and repeatedly named to the magazine’s Honor Roll of best hospitals in the nation; NewYork-Presbyterian Regional Hospital Network is comprised of leading hospitals in and around New York and delivers high-quality care to patients throughout the region; NewYork-Presbyterian Physician Services connects medical experts with patients in their communities; and NewYork-Presbyterian Community and Population Health features the hospital’s ambulatory care network sites and operations, community care initiatives and healthcare quality programs, including NewYork Quality Care, established by NewYork-Presbyterian, Weill Cornell and Columbia.

NewYork-Presbyterian is one of the largest healthcare providers in the U.S. Each year, nearly 29,000 NewYork-Presbyterian professionals deliver exceptional care to more than 2 million patients.

For more information, visit www.nyp.org and find us on Facebook, Twitter and YouTube.

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.